
|Articles|June 10, 2019
Neuroprotective implant for treatment of glaucoma in phase II trial
Author(s)Julianne Mobilian
Here's the latest innovations at Neurotech Pharmaceuticals, Inc.
Advertisement
Rich Small, CPA, CEO of
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA approves veligrotug-vvze (Lumvoa) for thyroid eye disease across active and chronic stages
2
Lesion growth rate reduction tops retina specialists' geographic atrophy treatment priorities
3
Obstructive sleep apnea and glaucoma: What a 12.5-million-patient data set reveals
4
ChatGPT-5 overestimates macular hole surgery success, study finds
5


























